Skip to main content

Study analyses incidence of pregnancy and disease-modifying therapy exposure trends in women with MS

A recent study, which set out to retrospectively determine incidence of pregnancy, disease-modifying therapy (DMT) exposure and pregnancy outcomes in women with relapsing remitting multiple sclerosis (RRMS), has revealed that DMT exposure during early pregnancy is increasing.

All women (9,098) with RRMS aged 15-45 years in the MSBase Registry during 2005-2016 were identified. Of those 9,098 women 1,178 women recorded 1,521 pregnancies.

A total of 635 (42%) reported pregnancies were conceived on DMT, increasing from 27% in 2006 to 62% in 2016. The median duration of DMT exposure during pregnancy was 30 days.

There were a higher number of induced abortions on US Food and Drug Administration (FDA) pregnancy class C/D drugs compared with pregnancy class B drugs and no DMT; but no differences in spontaneous abortions, term or preterm births.

This study was published by US National Library of Medicine National Institutes of Health.

Source: MS-UK, 10/01/19

Sub button for news stories - NP.jpg